Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
Fredy Chaparro-Rojas, Kathleen M MullaneDepartment of Medicine, Section of Infectious Diseases, University of Chicago, Chicago, IL, USAAbstract: The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an increase in the reported incidence, severity of cas...
Main Authors: | Chaparro-Rojas F, Mullane KM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-06-01
|
Series: | Infection and Drug Resistance |
Online Access: | http://www.dovepress.com/emerging-therapies-for-clostridium-difficile-infection-ndash-focus-on--a13502 |
Similar Items
-
Clostridium difficile infections and fidaxomicin treatment
by: Laura Fascio Pecetto
Published: (2014-12-01) -
Fidaxomicin - the new drug for Clostridium difficile infection
by: Chetana Vaishnavi
Published: (2015-01-01) -
Fidaxomicin: A Novel Agent for the Treatment of Clostridium difficile Infection
by: George G Zhanel, et al.
Published: (2015-01-01) -
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
by: Christine Lee, et al.
Published: (2016-01-01) -
Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin
by: Francesco Artom, et al.
Published: (2014-12-01)